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Abstract
Background: Carbapenem antibiotics are often used to treat bac-
terial infections that are refractory to other more commonly used 
antibiotics. The resilience of bacteria and their resistance mechanisms 
are of novel interest in the clinical setting, as antibiotic resistant bac-
teria are posing a challenge to health care professionals. The goal of 
this retrospective chart review was to isolate Carbapenem resistance 
among co-infections of Klebsiella and other microorganisms and to 
conduct a systematic review of this antibiotic resistance. 
Methods: This was a retrospective, single center chart review of 
patients admitted to Kingsbrook Jewish Medical Center from June 
2011 to June 2014. 
Study design: Retrospective Study, Chart Review.
Cases: Two patients met the criteria of the investigators and their 
charts were reviewed.
Results: Two cases with Klebsiella and E. coli co-infection with 
Carbapenem-resistant strains were identified. Patient 1 had a co-
infection of Klebsiella and E. coli. Initially, Klebsiella was carbape-
nem resistant, while E. coli was carbapenem susceptible. However, 
eventually both bacterial strains developed resistance. Patient 2 had 
a co-infection of Klebsiella and E. coli which were both carbapenem 
resistant. However, in contrast to Patient 1, Klebsiella became sus-
ceptible to carbapenem.
Conclusion: The findings indicate that carbapenem-resistant Kleb-
siella can be transient. Investigation is warranted to explore influence 
genetic traits, iatrogenic association and environmental causality of 
CRR.
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Introduction 
The use of carbapenem antibiotics such as imipe-
nem and meropenem has increased significantly in 
the past several years. This has been due to increa-
sed antibiotic resistance of many species of bacteria 
in the hospital setting associated with acquisition of 
one or more resistance mechanisms. Carbapenem 
antibiotics are often used to treat bacterial infections 
that have become refractory to antibiotic treatment 
attempts using other classes of antibiotics such as 
cephalosporins and aminoglycosides.
Recently, bacteria such as Klebsiella, E. coli, and E 
nterobacter have developed resistance to carbape-
nem antibiotics in the hospital setting. These types 
of microbes have been designated as carbapenem-
resistant Enterobacteriaceae (CRE) [1]. 
CRE is becoming a major problem for hospitali-
zed patients. As speculated by Goren et al., even 
for healthy individuals, CRE can often outcompete 
normal gut flora and therefore colonize the gut, 
which can become a source of infection for patients 
[1, 2, 3]. 
The mechanisms by which Enterobacteriaciae 
acquire and spread resistance to carbapenem an-
tibiotics have become a point of interest in current 
research. Mechanisms for transferring or developing 
resistance include plasmid transfer from species of 
CRE such as Klebsiella to other microorganisms, de-
creased porin expression in the outer membrane, 
and genetic mutations have been proposed as me-
chanisms of resistance [4]. 
The focus of this retrospective chart review was 
on patients who had a co-infection with carbape-
nem resistant Klebsiella and another microorganism, 
which ultimately acquired resistance to carbapenem, 
presumably by a resistance transfer mechanism. 
Methods
This study involved a retrospective, single center 
chart review of patients that were admitted to 
Kingsbrook Jewish Medical Center from June 2011 
to June 2014, who had positive cultures of both E. 
coli and Klebsiella. Resistance to carbapenam was 
reviewed on the microbiology report in the patient’s 
chart, and a timeline was constructed from the ini-
tial infection to resolution of infection, with special 
reference to the presence or change in carbapenem 
resistance. There was no distinction based on site 
of infection. 
Results
Based on patient chart analysis, two cases were 
found with Klebsiella and E. coli co-infection with 
carbapenem-resistant strains. Both patients were 
admitted from nursing home. Patient 1 had a co-
infection of Klebsiella and E. coli in a wound. Initia-
lly, Klebsiella was carbapenem resistant, while E. coli 
was carbapenem susceptible. One week later, when 
the wound culture was done again, both Klebsiella 
and E. coli were carbapenem resistant. Months af-
ter, the patient developed a Klebsiella infection in 
the urinary catheter that was carbapenem resistant. 
The patient had co morbidities such as living in a 
nursing home and having an indwelling catheter.
Patient 2 had an initial urinary tract infection with 
Klebsiella that was carbapenem resistant. Two wee-
ks later, the patient was found to be co-infected 
with Klebsiella and E. coli. that was carbapenem 
resistant. A clean catch urine specimen was con-
ducted two weeks later, and only E. coli was car-
bapenem resistant while Klebsiella was carbapenem 
sensitive. 
Discussion
One can speculate that in patient 1, the E. coli 
acquired carbapenem resistance transfered from 
Klebsiella. Urban et al. demonstrated the presence 
of E. coli harboring Klebsiella carbapenemase beta-
lactamases as a result of plasmid transfer from Kle-
bsiella to E. coli [5, 6]. In this scenario, Klebsiella 
would carry the genes titled KPC-2 and KPC-3, both 
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of which contribute to Klebsiella being resistant to 
carbapenem [7]. Interaction between Klebsiella and 
E. coli would enable plasmid transfer, and would 
confer the same carbapenem resistance to the E. 
coli. 
Another proposed mechanism of E. coli deve-
loping carbapenem resistannce would not involve 
Klebsiella gene transfer, but genetic mutations to 
the porin on the outer membrane of E. coli. It 
has been demonstrated that Enterobacteriaceae 
species, such as E. coli, can undergo genetic mu-
tations in genes such as OmpF and OmpC, which 
are responsible for porin production [7, 8]. Lack 
of porin production is associated with resistance 
to carbapenem, as the drug has no mechanism of 
crossing the cell membrane and gaining access into 
the bacteria [8, 9, 10]. 
Silencing of the marRAB operon in Enterobacte-
riaciae  species can also be proposed as a means 
of carbapenem resistance. The mar operon is also 
linked to porin expression. Studies by Chollet et al. 
demonstrate that this operon is influenced by the 
presence of antibotics [11, 12, 13]. The mar operon 
is regulated by marA and marR, with marA indu-
cing antibiotic resistance and marR, which down 
regulates antibiotic resistance [11, 12, 13]. MarA and 
marR are influenced by several factors, one of them 
being the bacteria's environment. If the bacteria is 
subjected to antibiotics, marA can be activated to 
induce resistance, while an environment without 
antibiotics would enable marR to be activated and 
down regulate antibiotic resistance [11, 12, 13]. It 
can be noted that while Klebsiella and E. coli share 
a similar genomes in regards to the mar operon, it 
is uncertain if factors from Klebsiella can influence 
the genome of E. coli [14].
Patient 1 had a long term wound infection that 
spanned several months. The patient was initially 
infected May 6, 2011 and continued to be infected 
until August 22, 2011. It should be noted that in 
the month of August, the patient's urinary cathe-
ter tested positive for Klebsiella that was resistant 
to carbapenem. One can speculate that long-term 
infection of the patient's wound would put the pa-
tient at a high risk for a secondary infection-in this 
case a catheter infection. Bisson et al. speculate that 
an important risk factor for developing an infection 
with bacteria exhibiting extended antibiotic resis-
tance properties is hospital stay [14]. Moreover, the 
CDC also supports this notion as the majority of 
cases of CRE are in patients who are in long-term 
care facilities [16]. 
Since the patient was in a nursing home, the in-
dividual would be at a greater risk of acquiring a 
secondary infection. As reported by CDC, the rate 
of CRE in a nursing home is 30%. Lowe et al. spe-
culate that long term care facilities, such as nur-
sing homes, have yet to develop standard protocol 
for treating patients that have CRE [17, 18]. Failure 
to consistently implement standard protocols for 
treatment and implementation of contact isolation 
precautions, puts individuals at risk for developing 
a secondary CRE infection or spreading the CRE in-
fection to other residents.
The medical timeline for patient 2 is presented 
below (Figure 1). The medical chart showed that 
there was an initial clean catch urine obtained on 
4/5/13 which grew only Carbapenem resistant Kle-
Figure 1.
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bsiella, A second urine collected on 4/16/13 showed 
both carbapenem resistant E coli and Klebsiella. On 
5/8/13 a third urine culture grew carbapenem re-
sistant E coli and carbapenem susceptible Klebsie-
lla. Chart review revealed the patient did not have 
any fever while under hospital care and no elevated 
WBC
One can only speculate why Klebsiella lost resis-
tance to carbapenem as evidenced by the culture 
results on 5/8/13. A possible explanation would re-
late to the marRAB operon and how it is regulated. 
The marRAB is influenced by the presence of an-
tibiotics [11, 12, 13]. Initially, when the patient had 
an E. coli and Klebsiella infection, the patient was 
receiving no antibiotic treatment and both species 
were carbapenem resistant. It can be hypothesized 
that after several weeks of no antibiotic treatment, 
there was induction of marR that would silence the 
marRAB sequence, which would result in increa-
sed porins, and therefore, increased susceptibility to 
carbapenem [19, 20]. One can speculate as to why 
Klebsiella lost resistance to imipenem and E. coli still 
retained resistance. The timing of gene regulation 
can provide an explanation for this. For instance, 
Klebsiella may induce marR quicker than E. coli so it 
would lose resistance at a faster rate and therefore 
be more susceptible earlier. The method of gene re-
gulation in bacteria can also provide an explanation 
to this. Induction of marR is regulated via a cascade. 
The mechanism of regulation of the marR cascade 
could be dependent on the bacteria species. Certain 
bacteria may regulate the gene cascade differently 
and therefore this would alter gene expression at 
varying rates. 
Conclusion:
Co-infections with carbapenem resistant strains of 
Klebsiella and E coli are a point of interest in medical 
microbiology. The findings suggests that carbape-
nem-resistant Klebsiella can influence genetic traits 
(i.e. transfer of carbapenem resistance) of other En-
terobacteriaceae such as E coli when present in the 
same environment or body site.
The phenomenon of carbapenem resistance 
transfer between different species of bacteria will 
likely cause more widespread carbapenem resistan-
ce and will greatly reduce the usefulness of some 
of potent antimicrobials
 Speculating that Klebsiella can down regulate 
certain genes can be of interest clinically. Rigorous 
antibiotic treatment can induce bacteria to up regu-
late resistance to antibiotics, and therefore, hinder 
resolution of an infection. Further investigation is 
needed to identify iatrogenic associations and cau-
sality of CRE in order to prevent further bacterial 
resistance and more importantly, spread of CRE. 
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